TAZORAC Drug Patent Profile

When do Tazorac patents expire, and what generic alternatives are available?

Tazorac is a drug marketed by Almirall and is included in two NDAs.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tazorac

A generic version of TAZORAC was approved as tazarotene by SUN PHARMA CANADA on April 3^rd, 2017.

Summary for TAZORAC

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	21
Patent Applications:	5,266
Drug Prices:	Drug price information for TAZORAC
What excipients (inactive ingredients) are in TAZORAC?	TAZORAC excipients list
DailyMed Link:	TAZORAC at DailyMed

See drug prices for TAZORAC

See drug sales revenues for TAZORAC

Recent Clinical Trials for TAZORAC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dana-Farber Cancer Institute	Phase 2
Bayer	Phase 2
Dr. Reddy's Laboratories Limited	Phase 2

See all TAZORAC clinical trials

Pharmacology for TAZORAC

Drug Class

Retinoid

US Patents and Regulatory Information for TAZORAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-001	Sep 29, 2000	AB	RX	Yes	Yes
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997	AB	RX	Yes	Yes
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	AB	RX	Yes	Yes
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997	AB	RX	Yes	Yes

Expired US Patents for TAZORAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-001	Sep 29, 2000
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997

International Patents for TAZORAC

See the table below for patents covering TAZORAC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	200284
Austria	76641
Australia	1326888
Australia	3659193
Australia	3735995
Australia	613346
Australia	674671

Supplementary Protection Certificates for TAZORAC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
0284288	SPC/GB98/002	United Kingdom		PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
0284288	12/1998	Austria		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203

TAZORAC market dynamics and financial trajectory: sales drivers, pricing pressure, payer access, and exclusivity risk

Last updated: July 26, 2026

TAZORAC (tazarotene) remains a narrow-dermatology product with demand tied to acne vulgaris and plaque psoriasis prescribing, payer step therapy, and generic competition risk. Financial trajectory is typically shaped by (1) penetration depth in topical acne and psoriasis formularies, (2) price erosion versus generic tazarotene brands, (3) channel inventory and seasonal skin-treatment patterns, and (4) exclusivity/Orange Book status affecting the timing and probability of generic launches.

What is the current market size and demand profile for TAZORAC (tazarotene) in acne and psoriasis?

TAZORAC demand is driven by two use cases that align with distinct prescriber behavior and payer coverage: acne vulgaris (commonly gel/cream formats) and plaque psoriasis (topical use). Market pull is constrained by topical utilization patterns, tolerability, and the availability of alternatives within retinoids and combination topicals.

Demand segmentation typically follows:

• Acne vulgaris: dermatology and primary-care prescribing, with higher sensitivity to formulary tiers and patient copays.
• Plaque psoriasis: more specialized prescribing, with stronger influence from step therapy and prior authorization.

Key commercial implications

• If payer coverage is “preferred” for tazarotene products, net sales hold up longer; if coverage is relegated to non-preferred tiers, patient switching accelerates.
• Format matters: gel and cream (and their relative tolerability and vehicle preferences) can shift share within the retinoid segment, even when the active is the same.

How do pricing, rebates, and payer contracting affect TAZORAC net sales?

Topical dermatology is contract-heavy. Net price is a function of list price offsets by rebates, copay cards, and payer-specific access rules.

Net sales are usually most exposed to:

• Rebate escalation after generic availability or after formulary reclassification.
• Loss of copay support effectiveness once payers impose copay caps.
• Pharmacy benefit manager (PBM) formulary steering toward lowest net cost generics.

Commercial KPI linkage

• Rising rebate rates tend to compress gross-to-net margins even if unit volume stays flat.
• When plan coverage shifts from preferred to non-preferred, volume drops can be larger than margin gains from lower wholesale acquisition cost.

What generic and competition dynamics threaten TAZORAC (tazarotene) revenue?

The central market dynamic is competition from generic tazarotene topical products. For a brand with an established active ingredient, financial trajectory generally follows a pattern: sustained share until a major generic entry wave, then a rapid decline in brand units accompanied by margin pressure.

Typical competitive sequence in topical retinoids

1. Pre-generic period: brand holds premium pricing with stable coverage.
2. First generic entries: payer coverage fragments, net pricing compresses.
3. Broad generic availability: PBMs steer to generics; brand share becomes “residual,” sustained only by specific physician preference, patient tolerability, or coverage exceptions.

What to watch for

• Pharmacy claims share shifts, not just ASP trends.
• Formulary changes by large PBMs and state Medicaid programs.
• Channel inventory: brands sometimes discount preemptively to avoid post-entry demand shock.

When does exclusivity end and how does Orange Book status affect TAZORAC generic entry risk?

Orange Book and Hatch-Waxman exclusivity status determine whether generic applicants can rely on Paragraph IV certifications and, in the presence of marketing exclusivity or use-patent blocks, delay entry.

Commercially relevant outcomes

• If Orange Book-listed patents are still in force for the specific marketed strengths and dosage forms, generic entry can be delayed until patent expiry or successful settlement.
• If fewer patents remain or if the patent estate is narrow (composition or generic-covering only), entry timing tends to follow the earliest actionable expiry.

Featured snippet answer (business framing) TAZORAC generic entry risk is tied to the earliest Orange Book patent expiry and whether any unexpired formulation or method-of-use patents remain listed for the exact NDCs and dosage forms.

What market share and revenue trajectory patterns occur after first generic launch?

For topical dermatology brands, the post-generic trajectory often shows:

• A steep volume decline in the first 3 to 6 months after a meaningful generic launch.
• A slower decline after that driven by intermittent switching resistance (tolerability) and insurance exceptions.
• Margin erosion due to rebate adjustments and competitive pricing.

Revenue bridge dynamics

• Unit volume drives the biggest step-change after the first broad generic entry.
• ASP does the second step-change via net price compression.

How does TAZORAC compare with other topical acne and psoriasis therapies in reimbursement and access?

TAZORAC competes across retinoids and topical dermatology classes where payers often favor stepwise treatment:

• Generic topical retinoids
• Topical antibiotics in acne pathways
• Anti-inflammatories and combination formulations for faster symptom control
• For psoriasis, non-retinoid topicals and vitamin D analogs with distinct prior authorization patterns

Competitive access reality

• Retinoid-only therapies can face narrower preference than combination products if payers pursue lower utilization of multi-ingredient regimens.
• However, if tazarotene is placed on preferred tiers within a retinoid sub-formulary, it can outperform less-covered alternatives.

What litigation, settlements, and Paragraph IV challenges affect TAZORAC financial outlook?

Patent litigation and Paragraph IV challenges influence launch timing through:

• Injunction risk (rarely realized in many settled cases but still influences bargaining)
• Automatic 30-month stay where applicable
• Settlement terms that set “carve-out” or deferred entry dates

Business impact Even when the brand does not permanently block entry, settlements often protect near-term revenue by delaying generic launches and stabilizing channel planning.

What FDA regulatory status and NDC-specific factors influence TAZORAC market performance?

For topical products, NDC-specific composition and strength listings matter to generics because applicants must match:

• Exact marketed strengths
• Dosage form and vehicle
• Packaging configurations

Practical consequence Brand revenue protection can persist longer if generics cannot “match” the exact labeled product without challenging patents for additional strengths or formulations.

What formulation and method-of-use patent coverage typically governs TAZORAC?

In topical dermatology, patent estates often cluster into:

• Composition-of-matter around the active
• Formulation patents tied to vehicle, concentration, or delivery attributes
• Method-of-use patents tied to acne dosing regimens or psoriasis treatment indications

Commercially decisive coverage Formulation or use-patent coverage can delay specific generic versions even when a composition patent expires. For financial trajectory, the question is less “do patents exist,” and more “are the remaining patents tied to the exact NDCs that drive sales?”

What manufacturing and supply chain risks affect TAZORAC availability and sales?

Availability shocks can cause:

• Temporary volume spikes (stockouts can shift demand to alternatives, then later return slowly)
• Contract renegotiations if supply constraints occur
• Inventory drawdowns that distort monthly sales and refill cycles

Common supply-chain exposures for topical brands

• Component pricing for creams and gels
• Cold-chain needs (usually less relevant for topical retinoids)
• Quality system remediation events that delay batch release

What commercial levers can sustain TAZORAC revenue post-competition?

Revenue retention levers in mature topical markets tend to be tactical:

• Targeted contracting with preferred formulary placement
• Support programs aligned to patient copay assistance rules
• Brand switching campaigns for dermatologists emphasizing tolerability or vehicle preference
• Negotiating rebates that maintain acceptable net price levels even as competitors enter

How strong is the TAZORAC patent estate for long-term exclusivity and what is the risk of erosion?

For a topical product, long-term exclusivity strength depends on how many distinct, enforceable patents remain for:

• Each marketed strength
• Each dosage form (gel vs cream)
• Each indication (acne vs plaque psoriasis)

Financial translation A dense patent estate typically correlates with later generic entry across all meaningful SKUs. A thin estate correlates with fast erosion once the earliest actionable patent expires.

How does TAZORAC revenue exposure typically look under different generic launch scenarios?

Scenario framework (business planning, not a forecast):

• Narrow generic entry: brand retains share in off-preferred plans and via dermatologist preference; net sales decline but may stabilize.
• Broad generic entry across PBMs: faster unit loss, sharp ASP and margin compression.
• Entry staggered by formulation strength: revenue declines in “waves” as generics obtain access to specific strengths first.

Key planning metrics

• Claims share by NDC and by formulary tier
• PBM rebate and preferred tier placements
• Wholesale and channel inventory turns

Key takeaways

• TAZORAC financial trajectory is dominated by payer access and generic competition dynamics in topical dermatology.
• Net sales hinge on gross-to-net effects: rebate escalation, tier placement, and patient copay sensitivity.
• Generic entry risk is governed by Orange Book-listed patents for the exact NDCs and dosage forms, plus whether litigation settlements defer entry.
• After meaningful generic launches, topical retinoid brands typically experience rapid unit and net price erosion, followed by residual share retention dependent on coverage exceptions and tolerability-driven prescribing.

FAQs

1) What are the primary drivers of TAZORAC prescriptions in acne vulgaris and plaque psoriasis?
Dermatology prescribing patterns, formulary tier placement, and step-therapy/prior authorization outcomes are the main drivers.

2) How quickly do topical dermatology brands lose share after generic entry?
Share typically declines fastest in the first 3 to 6 months after broad generic availability, then slows as coverage stabilizes.

3) What matters most for generic applicants targeting TAZORAC: active ingredient or NDC match?
NDC-specific match by strength and dosage form is critical for launch timing and patent infringement analysis.

4) Does Paragraph IV litigation meaningfully change TAZORAC’s near-term revenue?
It can, through settlement-driven launch deferrals and Paragraph IV stay mechanics tied to eligible filings.

5) Which payer actions most affect TAZORAC net price and volume?
Changes in PBM formulary preference, rebate contracting, copay steering policies, and Medicaid/state formulary updates most often drive the largest revenue swings.

References

1. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Guidance for Industry: Patent Listing Requirements and the Orange Book. U.S. Food and Drug Administration.
3. FDA. Hatch-Waxman Amendments framework and Paragraph IV certification overview. U.S. Food and Drug Administration.

DrugChatter Q&A for TAZORAC

What are the benefits of Tazorac?